Search Results
Your search for ,NOn matches 5550 pages
Showing 701 - 750Neoadjuvant/Adjuvant Pembrolizumab in Resectable NSCLC
On October 16, 2023, pembrolizumab was approved for use with platinum-containing chemotherapy as neoadjuvant treatment and as single-agent adjuvant treatment in patients with resectable (tumors ≥ 4 cm or node-positive) non–small cell lung cancer (NSCLC).1 Supporting Efficacy Data Approval was based ...
EGFR-Mutated Advanced NSCLC: CNS Efficacy With Combination of Osimertinib and Chemotherapy
In a subgroup analysis from the phase III FLAURA2 trial reported in the Journal of Clinical Oncology, Pasi A. Jänne, MD, PhD, and colleagues found the combination of osimertinib and chemotherapy improved central nervous system (CNS) efficacy vs osimertinib alone in the first-line treatment of...
All Adult Oncologists Are Geriatric Oncologists
The data developed over the past few years have overwhelmingly favored geriatric assessment as part of the routine care for older patients with cancer. It has become the standard of care. ASCO has recently published a Practical Geriatric Assessment to aid in the implementation of this vital...
Advanced NSCLC: Adding Canakinumab to First-Line Chemoimmunotherapy
As reported in the Journal of Clinical Oncology by Tan et al, the phase III CANOPY-1 trial has shown no survival benefits with the addition of canakinumab to first-line pembrolizumab plus chemotherapy in patients with advanced/metastatic non–small cell lung cancer (NSCLC) without EGFR or ALK...
DNA Mutational Profiling in Patients With Metastatic Colorectal Cancer
As reported in the Journal of Clinical Oncology by Innocenti et al, analysis of DNA mutational profiling in the phase III CALGB (Alliance)/SWOG 80405 trial of patients with metastatic colorectal cancer treated with bevacizumab or cetuximab with chemotherapy showed differences in outcome associated...
First-Line Treatment for Older Patients With Mantle Cell Lymphoma: Venetoclax Plus Standard Chemoimmunotherapy
The phase II PrE0405 trial met its primary endpoint, achieving a complete response rate of 85% in 33 patients with mantle cell lymphoma over age 60 who received bendamustine and rituximab, a standard chemoimmunotherapy regimen, along with venetoclax, which is investigational in this setting. The...
Understanding Racial and Ethnic Disparities in Modern AML Care After the Approval of Venetoclax
Use of venetoclax may increase survival in non-Hispanic Black patients with acute myeloid leukemia (AML), according to recent findings presented by Wang et al at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 955). Background Although the standard treatment...
Ibrutinib/Venetoclax in Relapsed/Refractory Mantle Cell Lymphoma
Patients with relapsed or refractory mantle cell lymphoma who received ibrutinib in combination with venetoclax experienced significantly better rates of progression-free survival compared with patients who received ibrutinib and placebo, according to findings from the international phase III...
Novel CAR T-Cell Therapy May Show Early Efficacy in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Early results from a new study have demonstrated that the novel chimeric antigen receptor (CAR) T-cell therapy AT101 resulted in favorable complete response rates at higher dose levels in patients with relapsed or refractory B-cell non-Hodgkin lymphoma, according to new findings simultaneously...
Encorafenib Plus Binimetinib in Metastatic NSCLC With BRAF V600E Mutation
On October 11, 2023, the BRAF inhibitor encorafenib (Braftovi) with the MEK inhibitor binimetinib (Mektovi) was approved for patients with metastatic non–small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by a U.S. Food and Drug Administration (FDA)-approved test.1,2 The FDA...
Expert Point of View: Kerin B. Adelson, MD, MHCDS
Discussant of these abstracts on the Oncology Care Model (OCM), Kerin B. Adelson, MD, MHCDS, Chief Quality and Value Officer at The University of Texas, MD Anderson Cancer Center, suggested the OCM was beneficial for both patients and health professionals despite the lack of clear positive ...
Expert Point of View: Upal Basu Roy, PhD, MPH
Upal Basu Roy, PhD, MPH, Executive Director of Research at the LUNGevity Foundation, in Chicago, shared his thoughts with The ASCO Post on the INCREASE trial’s findings and their potential impact on clinical practice. As Dr. Roy explained, neoadjuvant chemoimmunotherapy remains the current standard ...
INCREASE Trial: Immunotherapy Plus Chemoradiotherapy Doubles Complete Pathologic Response Rate in NSCLC
The integration of immunotherapy with traditional chemoradiotherapy has significantly increased pathologic complete response rates in patients with non–small cell lung cancer (NSCLC), according to data presented at the International Association for the Study of Lung Cancer 2023 World Conference on...
Antibody-Drug Conjugate Makes Progress as Second-Line Therapy for Advanced NSCLC
Datopotamab deruxtecan (Dato-DXd), a TROP-2–directed antibody-drug conjugate, improved progression-free survival by 25% on blinded independent committee review in previously treated patients with advanced or metastatic non–small cell lung cancer (NSCLC), and it was reported to be less toxic than...
Mark D. Tyson, MD, MPH, on High-Risk Non–Muscle-Invasive Bladder Cancer: A Potential New Treatment
Mark D. Tyson, MD, MPH, of the Mayo Clinic School of Graduate Medical Education, discusses the first results from BOND-003, a phase III study of intravesical cretostimogene grenadenorepvec monotherapy for patients with high-risk non–muscle-invasive bladder cancer that does not respond to Bacillus...
Lung-MAP Trial Demonstrates Potential of Public-Private Partnerships in Advancement of Cancer Therapy
The unique public-private partnership that undergirded the Lung-MAP trial for almost a decade may serve as a model for future clinical research that is more rapid, innovative, and inclusive, according to a recent report published by Herbst et al in Clinical Cancer Research. Background The Lung-MAP...
Risk-Adapted Radioimmunotherapy for Locally Advanced PD-L1–Positive NSCLC
In the phase II SPRINT trial reported in the Journal of Clinical Oncology, Ohri et al found that a chemotherapy-sparing regimen of pembrolizumab with risk-adapted radiotherapy was associated with good outcomes in patients with stage III or unresectable stage II non–small cell lung cancer (NSCLC)...
Highlights From the ESMO Congress 2023
The European Society for Medical Oncology (ESMO) Congress 2023 held in Madrid reported out several eagerly awaited and potentially practice-changing trials, bringing forward promising new combination strategies in the targeted and immunotherapy space, and put to the test selective agents against...
CodeBreaK 300: Sotorasib Plus Panitumumab of Benefit in KRAS-Mutated Metastatic Colorectal Cancer
The combination of sotorasib and panitumumab significantly improved progression-free survival compared with standard treatment in patients with chemotherapy-refractory metastatic colorectal cancer with KRAS G12C mutations, the phase III CodeBreaK 300 trial has shown. The KRAS G12C inhibitor...
Antibody-Drug Conjugate Makes Progress as Second-Line Therapy for Advanced NSCLC
Datopotamab deruxtecan (Dato-DXd), a TROP-2–directed antibody-drug conjugate, improved progression-free survival by 25% on blinded independent committee review in previously treated patients with advanced or metastatic non–small cell lung cancer (NSCLC), and it was reported to be less toxic than...
Expert Point of View: Marina C. Garassino, MD
Formal discussant of the ALINA trial Marina C. Garassino, MD, of the University of Chicago, agreed these results are “impressive and practice changing.” However, she said, at this point, more consideration is needed before jettisoning chemotherapy. “I don’t think we should stop giving adjuvant...
ALINA Trial: Anticancer Activity of Alectinib Reported in Earlier-Stage, ALK-Positive NSCLC
Treatment with the anaplastic lymphoma kinase (ALK) inhibitor alectinib significantly reduced the risk of recurrence or death by 76% (P < .0001) in patients with completely resected stage IB to IIIA ALK-positive non–small cell lung cancer (NSCLC) compared with platinum-based chemotherapy. This...
Expert Point of View: Zofia Piotrowska, MD
Zofia Piotrowska, MD, of the Massachusetts General Hospital/Harvard Medical School, Boston, noted that MARIPOSA and MARIPOSA-2 are “two well-designed, randomized phase III trials, each meeting its primary endpoints and representing important advances for patients with EGFR-mutant lung cancer.”...
Amivantamab-Based Regimens Show Anticancer Activity in EGFR-Mutated Advanced NSCLC
Widely anticipated findings from the MARIPOSA1 and MARIPOSA-22 trials were presented at the European Society for Medical Oncology (ESMO) Congress 2023, showing potentially improved outcomes with regimens incorporating the bispecific antibody amivantamab-vmjw for patients with advanced non–small...
Expert Point of View: Benjamin Besse, MD, PhD
“In patients with exon 20–mutated non–small cell lung cancer, PAPILLON established a new standard of care with amivantamab-vmjw and chemotherapy,” according to study discussant, Benjamin Besse, MD, PhD, Professor of Medical Oncology at Paris-Saclay University, Orsay, and Head of Clinical Research...
PAPILLON: Adding Amivantamab to First-Line Chemotherapy Prolongs Progression-Free Survival in NSCLC Subset
In the phase III PAPILLON trial, the addition of the bispecific antibody amivantamab-vmjw to chemotherapy resulted in a near doubling in median progression-free survival vs chemotherapy alone in patients with untreated non–small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR)...
Durvalumab May Offer Survival Benefit in Patients With NSCLC and Borderline Performance Status
The immune checkpoint inhibitor durvalumab may be safe and effective at improving overall survival in patients who have advanced or metastatic non–small cell lung cancer (NSCLC) and borderline performance status, according to a recent study published by Shaverdashvili et al in eClinicalMedicine....
Expert Point of View: Upal Basu Roy, PhD, MPH
Upal Basu Roy, PhD, MPH, Executive Director of Research at the LUNGevity Foundation, in Chicago, shared his thoughts with The ASCO Post on the INCREASE trial’s findings and their potential impact on clinical practice. As Dr. Roy explained, neoadjuvant chemoimmunotherapy remains the current standard ...
INCREASE Trial: Immunotherapy Plus Chemoradiotherapy Doubles Complete Pathologic Response Rate in NSCLC
The integration of immunotherapy with traditional chemoradiotherapy has significantly increased pathologic complete response rates in patients with non–small cell lung cancer (NSCLC), according to data presented at the International Association for the Study of Lung Cancer 2023 World Conference on...
Expert Point of View: Hiroaki Akamatsu, MD, PhD
Abstract discussant Hiroaki Akamatsu, MD, PhD, of Wakayama Medical University, Japan, highlighted the promising efficacy data supporting iruplinalkib, a highly selective, oral inhibitor of ALK and ROS1, in patients with ALK-positive non–small cell lung cancer (NSCLC). “The efficacy profile is very ...
Iruplinalkib Demonstrates Improved Efficacy and Tolerance vs Crizotinib in ALK Inhibitor–Naive, Advanced ALK-Positive NSCLC
The novel ALK tyrosine kinase inhibitor iruplinalkib has demonstrated potential for a difficult-to-treat subset of patients with non–small cell lung cancer (NSCLC), according to data presented at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer.1 A...
FLAURA2 Trial: Osimertinib Plus Chemotherapy Improves Outcomes in Advanced EGFR-Positive NSCLC
First-line treatment with osimertinib plus platinum-based chemotherapy achieved a statistically significant and clinically meaningful progression-free survival improvement compared with osimertinib alone in patients with advanced epidermal growth factor receptor (EGFR)-mutated non–small cell lung...
Highlights From the 2023 World Conference on Lung Cancer
The management of lung cancer and other thoracic malignancies has evolved significantly over the past decade. Thanks to many scientific advancements in the field, new therapeutic options, and improvements in screening and early detection, more patients are being cured, and many others are living...
National Academy of Medicine Elects New Members
The National Academy of Medicine recently announced the election of 100 members during its annual meeting, including 10 international members. Election to the Academy is considered one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated major...
Updates in Lower-Risk Myelodysplastic Syndromes/Neoplasms
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem cell disorders that are characterized by ineffective hematopoiesis, resulting in cytopenias, and they carry a risk of progression to acute myeloid leukemia (AML). In 2022, the fifth edition of the World Health ...
Small Study Identifies Safe, Effective Radiation Dose to Add to Neoadjuvant Chemotherapy and Durvalumab
Low-dose radiotherapy in combination with the monoclonal antibody durvalumab and chemotherapy as neoadjuvant therapy was well tolerated in patients with potentially resectable stage III non–small cell lung cancer (NSCLC), according to a small study conducted in China and presented at the...
Expert Point of View: Justin F. Gainor, MD
Discussant of the abstract on the ASTRUM-004 trial, Justin F. Gainor, MD, emphasized the significant, positive improvements in survival among patients randomly assigned to receive the PD-1 inhibitor serplulimab vs placebo. Dr. Gainor is Director of the Center for Thoracic Cancers Program, Director ...
ASTRUM-004: Serplulimab Plus Chemotherapy as First-Line Treatment of Advanced Squamous Non–Small Cell Lung Cancer
A novel treatment approach to squamous non–small cell lung cancer (NSCLC) may improve the prognosis for patients with previously limited treatment options, according to data presented at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer.1 Findings from ...
Expert Point of View: Bonnie Ky, MD, MSCE, FACC
Bonnie Ky, MD, MSCE, FACC, underscored the significant disparities in cardiovascular risk factors by race and ethnicity among adult survivors of childhood cancer, noting the increased risk of hypertension, diabetes, and obesity among non-Hispanic Black and Hispanic cancer survivors compared with...
Survivors of Childhood Cancer: Study Shows Heart-Related Ailments Linked to Radiotherapy Dose
Research on the advances in radiation modeling presented by Rebecca M. Howell, PhD, at the 2023 American Society for Radiation Oncology (ASTRO) Annual Meeting may provide insights into the late cardiac effects of survivors of childhood cancer in the Childhood Cancer Survivor Study (CCSS).1 Dr....
Expert Point of View: Solange Peters, MD, PhD and Upal Basu Roy, PhD, MPH
Commenting on the AEGEAN study at the 2023 World Conference on Lung Cancer were the abstract’s invited discussant Solange Peters, MD, PhD, Professor and Chair of Medical Oncology and the Thoracic Malignancies Program at Lausanne University Hospital in Switzerland, and Upal Basu Roy, PhD, MPH,...
Perioperative Durvalumab Improves Surgical Outcomes in Resectable NSCLC: Phase III AEGEAN Trial
The addition of durvalumab to neoadjuvant chemotherapy led to higher rates of R0 resections and posed no apparent impediments to successful surgery for resectable non–small cell lung cancer (NSCLC), according to findings from the randomized phase III AEGEAN trial presented at the International...
Benjamin Besse, MD, PhD, on NSCLC: Safety and Efficacy Data on Novel Bispecific Antibody
Benjamin Besse, MD, PhD, of the Gustave Roussy Cancer Centre, discusses new findings on AZD7789, which targets PD-1 and TIM-3, in patients with stage IIIB–IV non–small cell lung cancer (NSCLC) with previous anti–PD-L1 therapy. This bispecific antibody showed manageable safety and preliminary...
Early Breast Cancer: Effect of Radiotherapy to Regional Nodes
As reported in The Lancet by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), an individual patient meta-analysis has shown that more recent—but not older—trials of regional lymph node radiotherapy vs no radiotherapy in patients with early breast cancer showed benefits of...
FDA Approves Next-Generation Tyrosine Kinase Inhibitor Repotrectinib for ROS1-Positive NSCLC
On November 15, 2023, the U.S. Food and Drug Administration (FDA) approved the next-generation tyrosine kinase inhibitor repotrectinib (Augtyro) for the treatment of locally advanced or metastatic ROS1-positive non–small cell lung cancer (NSCLC). According to the American Lung Association, the ROS1 ...
Racial Disparities in Guideline-Concordant Care in Early-Onset Colorectal Cancer in the United States
In a study reported in the Journal of Clinical Oncology, Nogueira et al found that among U.S. Black and White patients with early-onset colorectal cancer, Black patients were more likely to receive poorer and less timely care. As stated by the investigators: “Young individuals racialized as Black...
Benjamin Besse, MD, PhD, on EGFR-Mutated NSCLC: Update on Patritumab Deruxtecan in Previously Treated Disease
Benjamin Besse, MD, PhD, of the Gustave Roussy Cancer Centre, discusses phase II findings from the HERTHENA-Lung01 study, which showed patients with previously treated EGFR-mutated non–small cell lung cancer may benefit from the antibody-drug conjugate patritumab deruxtecan after EGFR tyrosine...
Osimertinib With or Without Chemotherapy in EGFR-Mutant Advanced NSCLC
As reported in The New England Journal of Medicine by Planchard et al, the phase III FLAURA2 trial has shown superior progression-free survival with osimertinib plus platinum-based chemotherapy vs osimertinib alone in the first-line treatment of EGFR-mutant advanced non–small cell lung cancer...
Results of PACIFIC Trial Being Replicated in Real-World Settings
Real-world outcomes often fall short of those achieved in clinical trials, but this is apparently not so for patients receiving chemoradiotherapy plus consolidation with durvalumab in unresectable stage III non–small cell lung cancer (NSCLC). The robust results achieved in the phase III PACIFIC...
Addition of Tumor Treating Fields Therapy to Standard Systemic Therapy Improves Survival in Metastatic NSCLC after Progression on Platinum-Based Therapy
In a phase III trial (LUNAR) reported in The Lancet Oncology, Ticiana Leal, MD, Winship Cancer Institute at Emory University, and colleagues found that the addition of Tumor Treating Fields (TTFields) therapy to standard systemic therapy improved overall survival in patients with metastatic...
